Substance Use Tools & Resources    

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.

These are slides from a webinar which provided an overview of how drug diversion is a significant risk for patients and institutions and addresses why institutions should have a program in place to detect diversion.

Provides facts about the benefits of using PDMPs for prescribers, pharmacists, patients, and regulatory and law enforcement agencies.

Provides guidance to physicians and pharmacists on buprenorphine regulatory requirements, prescribing, dispensing, and safety recommendations and additional information to improve decision making and promote beneficial outcomes.

A book for clients to record ideas and reminders that will strengthen their recovery and help them stay abstinent.

This manual contains all the materials necessary for a counselor to conduct individual and group sessions using the Matrix Intensive Outpatient Treatment for People with Stimulant Use Disorders (IOP) approach.

This manual provides counselors with an overview of the Family Education component of the Matrix Intensive Outpatient Treatment for People with Stimulant Use Disorders (IOP) package and general guidelines for conducting sessions.

This manual provides guidelines for administrators on addressing issues in outpatient treatment for alcohol and substance misuse. It discusses cultural competence, management and strategic collaborations, human resources, financing, and performance and outcomes improvement.

Provides guidance on the use of buprenorphine among a number of topics, including physiology and pharmacology of opioids, opioid addiction, and buprenorphine treatment; screening and assessment of OUDs; protocols for buprenorphine treatment; management of special populations; and policies and procedures related to DATA 2000.